Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2013, Article ID 350169, 7 pages
http://dx.doi.org/10.1155/2013/350169
Review Article

Current Challenges to the United States’ AIDS Drug Assistance Program and Possible Implications of the Affordable Care Act

1Department of Medicine, University of Virginia, Charlottesville, VA 22903, USA
2Department of Public Health Sciences, University of Virginia, Charlottesville, VA 22908-0717, USA
3Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, P.O. Box 801379, Charlottesville, VA 22908, USA

Received 10 May 2012; Revised 8 December 2012; Accepted 5 February 2013

Academic Editor: Glenda Gray

Copyright © 2013 Kathleen A. McManus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Health Resources and Services Administration, HIV/AIDS Bureau, Ryan White HIV/AIDS Program Progress Report. U.S. Department of Health and Human Services, 2008, http://hab.hrsa.gov/data/files/2008progressrpt.pdf.
  2. J. V. Baker and K. Henry, “If we can't get what we want, can we get what we need? optimizing use of antiretroviral therapy in the current Era,” Annals of Internal Medicine, vol. 154, no. 8, pp. 563–565, 2011. View at Google Scholar · View at Scopus
  3. National Alliance of States and Territorial AIDS Directors (NASTAD), National ADAP Monitoring Project Annual Report Module One, January 2012, http://www.nastad.org/Docs/080758_Module%20One%20-%20National%20ADAP%20Monitoring%20Project%20Annual%20Report%20-%20January%202012.pdf.
  4. NASTAD, National ADAP Monitoring Project Annual Report, May 2011, http://www.nastad.org/Docs/020035_2011%20NASTAD%20National%20ADAP%20Monitoring%20Project%20Annual%20Report.pdf.
  5. NASTAD, Henry J. Kaiser Family Foundation, National ADAP Monitoring Project Annual Report, April 2005, http://www.kff.org/hivaids/loader.cfm?url=/commonspot/security/getfile.cfm&PageID=52593.
  6. NASTAD, The ADAP Watch, August 2010, http://www.nastad.org/Docs/Public/InFocus/201086_ADAP%20Watch%20update%20-%208.6.10.pdf.
  7. NASTAD, ADAP Watch, August 2011, http://www.nastad.org/Files/041808_NASTAD%20ADAP%20Watch%20-%20August%202011.pdf.
  8. NASTAD, ADAP Watch, November 2011, http://nastad.org/Docs/025447_NASTAD%20ADAP%20Watch%20-%20November%202011.pdf.
  9. NASTAD, The ADAP Watch, February 2012, http://www.nastad.org/Docs/012251_ADAP%20Watch%20update%20-%202.24.12.pdf.
  10. NASTAD, NASTAD Applauds President’s Commitment to ADAP; Continued Commitment from Pharmaceutical Partners and State Governments Remain Critical, December 2011, http://lgbtpov.frontiersla.com/2011/12/01/world-aids-day-statements-and-reaction-to-president-obamas-remarks/.
  11. NASTAD, National ADAP Monitoring Project Annual Report Module One, August 2012, http://www.nastad.org/Docs/021503_National%20ADAP%20Monitoring%20Project%20Annual%20Report%20-%20August%202012.pdf.
  12. NASTAD, ADAP Watch, November 2012, http://www.nastad.org/Docs/120048_NASTAD%20ADAP%20Watch%20-%2011.19.12.pdf.
  13. NASTAD, A Coordinated Strategy to Save America’s ADAPs, May 2011, http://www.nastad.org/Docs/022257_ADAP%20Crisis%20Strategy%20-%20May%2011,%202011.pdf.
  14. Panel on Antiretroviral Guidelines for Adults and Adolescents, “Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,” Department of Health and Human Services, March 2012, http://aidsinfo.nih.gov/guidelines.
  15. Centers for Disease Control and Prevention (CDC), “HIV surveillance—United States, 1981–2008,” Morbidity and Mortality Weekly Report, vol. 60, no. 21, pp. 689–693, 2011. View at Google Scholar · View at Scopus
  16. Centers for Disease Control and Prevention, “Revised recommendations for HIV testing of adults, adolescents and pregnant women in health-care settings,” Morbidity and Mortality Weekly Report, vol. 55, pp. 1–24, 2006. View at Google Scholar
  17. Ryan White HIV/AIDS Treatment Extension Act of 2009 (Public Law 111-87).
  18. I. V. Bassett, C. Farel, E. D. Szmuilowicz, and R. P. Walensky, “AIDS Drug Assistance Programs in the era of routine HIV testing,” Clinical Infectious Diseases, vol. 47, no. 5, pp. 695–701, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Y. Kim and P. Farmer, “AIDS in 2006—moving toward one world, one hope?” New England Journal of Medicine, vol. 355, no. 7, pp. 645–647, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Hanssens, “Legal and ethical implications of opt-out HIV testing,” Clinical Infectious Diseases, vol. 45, no. 4, pp. S232–S239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. J. Mugavero, W. E. Norton, and M. S. Saag, “Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system,” Clinical Infectious Diseases, vol. 52, no. 2, pp. S238–S246, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. S. Crowley, J. Kates, and Henry J. Kaiser Family Foundation, The Affordable Care Act, the Supreme Court, and HIV: What are the Implications? September 2012, http://www.kff.org/hivaids/upload/8363.pdf.
  23. B. R. Schackman, K. A. Gebo, R. P. Walensky et al., “The lifetime cost of current human immunodeficiency virus care in the United States,” Medical Care, vol. 44, no. 11, pp. 990–997, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. B. P. Linas, H. Zheng, E. Losina et al., “Optimizing resource allocation in United States AIDS Drug Assistance programs,” Clinical Infectious Diseases, vol. 43, no. 10, pp. 1357–1364, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. B. P. Linas, E. Losina, A. Rockwell, R. P. Walensky, K. Cranston, and K. A. Freedberg, “Improving outcomes in state AIDS drug assistance programs,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 5, pp. 513–521, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. Virginia Department of Health, Virginia AIDS Drug Assistance Program (ADAP) Updates, November 2011, http://www.vdh.state.va.us/epidemiology/DiseasePrevention/Programs/ADAP/updates.htm.
  27. O. J. Blackstock, K. H. Wang, and D. A. Fiellin, “State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors,” Journal of General Internal Medicine, vol. 26, pp. 1426–1433, 2011. View at Google Scholar
  28. C. Smith and Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group, “Association between modifiable and non-modifiable risk factors and specific causes of death in the HAART era: the Data Collection on Adverse Events of Anti-HIV Drug Study,” in Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections, Abstract 145, Montreal, Canada, February 2009.
  29. N. Friis-Møller, R. Weber, P. Reiss et al., “Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study,” AIDS, vol. 17, no. 8, pp. 1179–1193, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. Health Resources and Services Administration, Pharmacy Affairs & 340B Drug Pricing Program, http://www.hrsa.gov/index.html.
  31. J. Kates and Henry J. Kaiser Family Foundation, Medicaid and HIV: A National Analysis, October 2011, http://www.kff.org/hivaids/upload/8218.pdf.
  32. T. C. Quinn, M. J. Wawer, N. Sewankambo et al., “Viral load and heterosexual transmission of human immunodeficiency virus type 1,” New England Journal of Medicine, vol. 342, no. 13, pp. 921–929, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Castilla, J. Del Romero, V. Hernando, B. Marincovich, S. García, and C. Rodríguez, “Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV,” Journal of Acquired Immune Deficiency Syndromes, vol. 40, no. 1, pp. 96–101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. T. C. Porco, J. N. Martin, K. A. Page-Shafer et al., “Decline in HIV infectivity following the introduction of highly active antiretroviral therapy,” AIDS, vol. 18, no. 1, pp. 81–88, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. M. S. Cohen, Y. Q. Chen, M. McCauley et al., “Prevention of HIV-1 infection with early antiretroviral therapy,” New England Journal of Medicine, vol. 365, no. 6, pp. 493–505, 2011. View at Publisher · View at Google Scholar
  36. S. M. Blower, H. B. Gershengorn, and R. M. Grant, “A tale of two futures: HIV and antiretroviral therapy in San Francisco,” Science, vol. 287, no. 5453, pp. 650–654, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. R. M. Granich, C. F. Gilks, C. Dye, K. M. De Cock, and B. G. Williams, “Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model,” The Lancet, vol. 373, no. 9657, pp. 48–57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. AIDS Healthcare Foundation, Drug Pricing, October 2011, http://www.aidshealth.org/archives/1822.
  39. Virginia Department of Health, Virginia HIV Epidemiology Profile 2011: Care & Service Utilization, September 2011, http://www.vdh.state.va.us/epidemiology/DiseasePrevention/Profile2011/HCS_2011.pdf.
  40. L. Chibbaro, “AIDS drugs cut off for Va. ADAP patients,” Washington Blade, February 2011, http://www.washingtonblade.com/2011/02/10/aids-drugs-cut-off-for-va-adap-patients/.
  41. R. Solotaroff, J. Devoe, B. J. Wright et al., “Medicaid programme changes and the chronically ill: early results from a prospective cohort study of the Oregon Health Plan,” Chronic Illness, vol. 1, no. 3, pp. 191–205, 2005. View at Google Scholar · View at Scopus
  42. W. M. El-Sadr, J. D. Lundgren, J. D. Neaton et al., “CD4+ count-guided interruption of antiretroviral treatment,” New England Journal of Medicine, vol. 355, no. 22, pp. 2283–2296, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. Henry J. Kaiser Family Foundation, Focus on Healthcare Reform: A Guide to the Supreme Court’s Affordable Care Act Decision, July 2012, http://www.kff.org/healthreform/upload/8332.pdf.
  44. M. J. Mugavero, H. Y. Lin, J. H. Willig et al., “Missed visits and mortality among patients establishing initial outpatient HIV treatment,” Clinical Infectious Diseases, vol. 48, no. 2, pp. 248–256, 2009. View at Publisher · View at Google Scholar · View at Scopus